Use of readily accessible inflammatory markers to predict diabetic kidney disease

Lauren Winter, Lydia A. Wong, George Jerums, Jas Mine Seah, Michele Clarke, Sih Min Tan, Melinda T. Coughlan, Richard J. MacIsaac, Elif I. Ekinci

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Diabetic kidney disease is a common complication of type 1 and type 2 diabetes and is the primary cause of end-stage renal disease in developed countries. Early detection of diabetic kidney disease will facilitate early intervention aimed at reducing the rate of progression to end-stage renal disease. Diabetic kidney disease has been traditionally classified based on the presence of albuminuria. More recently estimated glomerular filtration rate has also been incorporated into the staging of diabetic kidney disease. While albuminuric diabetic kidney disease is well described, the phenotype of non-albuminuric diabetic kidney disease is now widely accepted. An association between markers of inflammation and diabetic kidney disease has previously been demonstrated. Effector molecules of the innate immune system including C-reactive protein, interleukin-6, and tumor necrosis factor-a are increased in patients with diabetic kidney disease. Furthermore, renal infiltration of neutrophils, macrophages, and lymphocytes are observed in renal biopsies of patients with diabetic kidney disease. Similarly high serum neutrophil and low serum lymphocyte counts have been shown to be associated with diabetic kidney disease. The neutrophil-lymphocyte ratio is considered a robust measure of systemic inflammation and is associated with the presence of inflammatory conditions including the metabolic syndrome and insulin resistance. Cross-sectional studies have demonstrated a link between high levels of the above inflammatory biomarkers and diabetic kidney disease. Further longitudinal studies will be required to determine if these readily available inflammatory biomarkers can accurately predict the presence and prognosis of diabetic kidney disease, above and beyond albuminuria, and estimated glomerular filtration rate.

Original languageEnglish
Article number225
Number of pages17
JournalFrontiers in Endocrinology
Volume9
Issue numberMAY
DOIs
Publication statusPublished - 22 May 2018

Keywords

  • Atherosclerosis
  • Diabetic kidney disease
  • Diabetic nephropathy
  • Inflammation
  • Lymphocytes
  • Neutrophil-lymphocyte ratio
  • Neutrophils

Cite this

Winter, L., Wong, L. A., Jerums, G., Seah, J. M., Clarke, M., Tan, S. M., ... Ekinci, E. I. (2018). Use of readily accessible inflammatory markers to predict diabetic kidney disease. Frontiers in Endocrinology, 9(MAY), [225]. https://doi.org/10.3389/fendo.2018.00225
Winter, Lauren ; Wong, Lydia A. ; Jerums, George ; Seah, Jas Mine ; Clarke, Michele ; Tan, Sih Min ; Coughlan, Melinda T. ; MacIsaac, Richard J. ; Ekinci, Elif I. / Use of readily accessible inflammatory markers to predict diabetic kidney disease. In: Frontiers in Endocrinology. 2018 ; Vol. 9, No. MAY.
@article{0f137c2f6ae94ee6950b38e6b362149e,
title = "Use of readily accessible inflammatory markers to predict diabetic kidney disease",
abstract = "Diabetic kidney disease is a common complication of type 1 and type 2 diabetes and is the primary cause of end-stage renal disease in developed countries. Early detection of diabetic kidney disease will facilitate early intervention aimed at reducing the rate of progression to end-stage renal disease. Diabetic kidney disease has been traditionally classified based on the presence of albuminuria. More recently estimated glomerular filtration rate has also been incorporated into the staging of diabetic kidney disease. While albuminuric diabetic kidney disease is well described, the phenotype of non-albuminuric diabetic kidney disease is now widely accepted. An association between markers of inflammation and diabetic kidney disease has previously been demonstrated. Effector molecules of the innate immune system including C-reactive protein, interleukin-6, and tumor necrosis factor-a are increased in patients with diabetic kidney disease. Furthermore, renal infiltration of neutrophils, macrophages, and lymphocytes are observed in renal biopsies of patients with diabetic kidney disease. Similarly high serum neutrophil and low serum lymphocyte counts have been shown to be associated with diabetic kidney disease. The neutrophil-lymphocyte ratio is considered a robust measure of systemic inflammation and is associated with the presence of inflammatory conditions including the metabolic syndrome and insulin resistance. Cross-sectional studies have demonstrated a link between high levels of the above inflammatory biomarkers and diabetic kidney disease. Further longitudinal studies will be required to determine if these readily available inflammatory biomarkers can accurately predict the presence and prognosis of diabetic kidney disease, above and beyond albuminuria, and estimated glomerular filtration rate.",
keywords = "Atherosclerosis, Diabetic kidney disease, Diabetic nephropathy, Inflammation, Lymphocytes, Neutrophil-lymphocyte ratio, Neutrophils",
author = "Lauren Winter and Wong, {Lydia A.} and George Jerums and Seah, {Jas Mine} and Michele Clarke and Tan, {Sih Min} and Coughlan, {Melinda T.} and MacIsaac, {Richard J.} and Ekinci, {Elif I.}",
year = "2018",
month = "5",
day = "22",
doi = "10.3389/fendo.2018.00225",
language = "English",
volume = "9",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media",
number = "MAY",

}

Use of readily accessible inflammatory markers to predict diabetic kidney disease. / Winter, Lauren; Wong, Lydia A.; Jerums, George; Seah, Jas Mine; Clarke, Michele; Tan, Sih Min; Coughlan, Melinda T.; MacIsaac, Richard J.; Ekinci, Elif I.

In: Frontiers in Endocrinology, Vol. 9, No. MAY, 225, 22.05.2018.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Use of readily accessible inflammatory markers to predict diabetic kidney disease

AU - Winter, Lauren

AU - Wong, Lydia A.

AU - Jerums, George

AU - Seah, Jas Mine

AU - Clarke, Michele

AU - Tan, Sih Min

AU - Coughlan, Melinda T.

AU - MacIsaac, Richard J.

AU - Ekinci, Elif I.

PY - 2018/5/22

Y1 - 2018/5/22

N2 - Diabetic kidney disease is a common complication of type 1 and type 2 diabetes and is the primary cause of end-stage renal disease in developed countries. Early detection of diabetic kidney disease will facilitate early intervention aimed at reducing the rate of progression to end-stage renal disease. Diabetic kidney disease has been traditionally classified based on the presence of albuminuria. More recently estimated glomerular filtration rate has also been incorporated into the staging of diabetic kidney disease. While albuminuric diabetic kidney disease is well described, the phenotype of non-albuminuric diabetic kidney disease is now widely accepted. An association between markers of inflammation and diabetic kidney disease has previously been demonstrated. Effector molecules of the innate immune system including C-reactive protein, interleukin-6, and tumor necrosis factor-a are increased in patients with diabetic kidney disease. Furthermore, renal infiltration of neutrophils, macrophages, and lymphocytes are observed in renal biopsies of patients with diabetic kidney disease. Similarly high serum neutrophil and low serum lymphocyte counts have been shown to be associated with diabetic kidney disease. The neutrophil-lymphocyte ratio is considered a robust measure of systemic inflammation and is associated with the presence of inflammatory conditions including the metabolic syndrome and insulin resistance. Cross-sectional studies have demonstrated a link between high levels of the above inflammatory biomarkers and diabetic kidney disease. Further longitudinal studies will be required to determine if these readily available inflammatory biomarkers can accurately predict the presence and prognosis of diabetic kidney disease, above and beyond albuminuria, and estimated glomerular filtration rate.

AB - Diabetic kidney disease is a common complication of type 1 and type 2 diabetes and is the primary cause of end-stage renal disease in developed countries. Early detection of diabetic kidney disease will facilitate early intervention aimed at reducing the rate of progression to end-stage renal disease. Diabetic kidney disease has been traditionally classified based on the presence of albuminuria. More recently estimated glomerular filtration rate has also been incorporated into the staging of diabetic kidney disease. While albuminuric diabetic kidney disease is well described, the phenotype of non-albuminuric diabetic kidney disease is now widely accepted. An association between markers of inflammation and diabetic kidney disease has previously been demonstrated. Effector molecules of the innate immune system including C-reactive protein, interleukin-6, and tumor necrosis factor-a are increased in patients with diabetic kidney disease. Furthermore, renal infiltration of neutrophils, macrophages, and lymphocytes are observed in renal biopsies of patients with diabetic kidney disease. Similarly high serum neutrophil and low serum lymphocyte counts have been shown to be associated with diabetic kidney disease. The neutrophil-lymphocyte ratio is considered a robust measure of systemic inflammation and is associated with the presence of inflammatory conditions including the metabolic syndrome and insulin resistance. Cross-sectional studies have demonstrated a link between high levels of the above inflammatory biomarkers and diabetic kidney disease. Further longitudinal studies will be required to determine if these readily available inflammatory biomarkers can accurately predict the presence and prognosis of diabetic kidney disease, above and beyond albuminuria, and estimated glomerular filtration rate.

KW - Atherosclerosis

KW - Diabetic kidney disease

KW - Diabetic nephropathy

KW - Inflammation

KW - Lymphocytes

KW - Neutrophil-lymphocyte ratio

KW - Neutrophils

UR - http://www.scopus.com/inward/record.url?scp=85047451105&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00225

DO - 10.3389/fendo.2018.00225

M3 - Review Article

VL - 9

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - MAY

M1 - 225

ER -